N/A N=478 Adaptive Cardiac Resynchronization Therapy Study
Heart Failure
Primary: Percentage of Patients With Improved Heart Failure Outcomes Clinical Composite Score — 234; 114 Participants — p=0.0002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=76 Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Melanoma (Skin)
Primary: Tumor Response Rate, as Measured by RECIST Criteria — 8.8; 25.6 percentage of participants
Phase 1 N=20 A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Solid Tumor · Pancreatic Cancer
Primary: Number of Participants Who Experienced Any Dose-Limiting Toxicity (DLT) During First Cycle - Day 1 to 28 — 0; 0; 1; 0 Participants
N/A N=1,737 Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Patients With Therapeutic Success at Week 6 (Approx.) (Visit 2). — 51.52 Percentage of patients
N/A N=485 Study of Binocular Computer Activities for Treatment of Amblyopia
Amblyopia
Primary: Change in Distance Visual Acuity From Baseline in the Younger Cohort (5 to <13 Years) — 1.05; 1.35; 1.08; 1.32 LogMAR lines
Phase 2 N=8 A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung · Adenocarcinoma
Primary: Progression-free Survival (PFS) — 5.2; 7.2 weeks
Phase 3 N=1,199 A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Prostate Neoplasms
Primary: Radiographic Progression-Free Survival (PFS) — 33.02; 14.78 Months — p=<0.0001
Phase 3 N=371 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma · Gastric Cancer Third Line
Primary: Overall Survival (OS) — 5.0; 4.6 months — p=0.8078
N/A N=47 Healthy Bodies, Healthy Kids
Child Mental Disorders · Obesity · Metabolic Syndrome
Primary: DEXA-measured Adiposity — 0.76; -0.43; -2.79 kilograms — p=0.01
Phase 1 N=97 Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers
Healthy Adult Subjects · Healthy Elderly Subjects
Primary: Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16 - Alertness — 2.16; 7.50; 6.71; 3.50 Units on a scale
N/A N=90 Clinical Evaluation of the Safety and Efficacy of FID 120947A
Refractive Error
Primary: Percentage of Eyes With Visibly Clean Lenses at Each Visit — 92.2; 88.2; 95.5; 92.5 percentage of eyes
Phase 4 N=108 Brilinta Taiwan Post Approval Safety Study
Non ST-elevation Myocardial Infarction
Primary: Number of Participants With Fatal/Life-threatening Bleedings — 4 Participants
Phase 2 N=22 Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Recurrent Osteosarcoma
Primary: Disease Control Success — 3 Participants
N/A N=102 Iron Parameters in Non-anemic First Trimester Gravidas
Iron Deficiency (Without Anemia) · Pregnancy
Primary: Percent of Non-anemic Patients With Iron Deficiency Stratified by Gravidity — 9; 3; 6; 38 Participants
Phase 2 N=24 Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)
Metachromatic Leukodystrophy (MLD)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Type and Severity — 6; 6; 6; 6 Participants